



LASA SUPERGENERICS LIMITED

CORPORATE OFFICE: B/207, City Point, Near Kohinoor Hotel, J B Nagar (Chakala) Metro Station, Andheri (E), Mumbai – 400059, Maharashtra, India,
Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: www.lasalabs.com

Ref. No.: LASA/SE/19-20/47

Tuesday February 11, 2020

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Sub: Newspaper Advertisement

Pursuant to Regulation 47 of the Securities and Exchange Board of the India (Listing Obligation and Disclosure Requirement) Regulation, 2015, please find enclosed herewith copies of newspaper advertisements in the following newspaper:

1. ***Business Standard on February 11,2020***
2. ***Mumbai Lakhsdeep on February 11,2020***

Please take the same on your records.

Thanking You
For Lasa Supergenerics Limited

Nidhi Kulshreshtha
Company Secretary and Compliance Officer

Place : Chennai
Date : 10-02-2020



LASA SUPERGENERICS LIMITED

REG OFF: C-105, MIDC, MAHAD, DIST - RAIGAD, MAHAD - 402309
CORPORATE OFFICE: B-207, CITIPOINT, NEAR KOHINOOR HOTEL,
J.B. NAGAR, ANDHERI (E), MUMBAI - 400059,
TEL: +91 22 4970 1092 WEBSITE: WWW.LASALABS.COM, EMAIL ID: INVESTOR@LASALABS.COM
CIN: L24233MH2016PLC274202

Statement of Unaudited Financial Results for the Quarter and Nine months ended 31 December, 2019 (Rs. In Lakhs)

Particulars	Quarter ended			Nine Months Ended		Year ended
	31.12.2019 (Unaudited)	30.09.2019 (Unaudited)	31.12.2018 (Unaudited)	31.12.2019 (Unaudited)	31.12.2018 (Unaudited)	31.03.2019 (Audited)
1. INCOME						
a. Revenue from Operations	3,928.97	4,041.19	5,388.38	11,868.56	12,754.92	16,957.30
b. Other Income	31.95	5.24	88.34	46.36	294.20	47.45
Total Income	3,960.91	4,046.44	5,476.72	11,914.92	13,049.12	17,004.75
2. Expenses						
a. Cost of Materials consumed	1,931.24	1,917.67	2,606.24	6,157.41	6,091.86	8,380.65
b. Cost of Traded Goods	-	-	1,582.40	49.41	3,356.31	4,240.38
c. Change in Inventories of Finished Goods, Work-in-Progress and Stock in trade	245.85	481.18	500.29	1,026.91	357.36	173.62
d. Employee benefits expenses	350.80	349.08	297.71	999.51	851.86	1,173.51
e. Finance costs	174.07	199.98	193.77	588.07	952.45	837.88
f. Depreciation & amortizations expenses	439.65	432.20	487.22	1,298.08	1,452.42	1,930.85
g. Other Expenses	584.65	542.49	464.64	1,564.99	1,294.08	1,878.14
Total Expenses (a to g)	3,726.26	3,922.60	6,132.27	11,684.38	14,356.33	18,615.03
Exceptional Items	-	-	-	-	-	-
3. Profit / (Loss) before tax (1-2)	234.65	123.83	(655.55)	230.54	(1,307.21)	(1,610.28)
4. Tax expense						
Current Tax	42.54	-	-	42.54	-	-
Deferred Tax	(102.28)	169.03	(127.68)	46.42	(354.83)	(468.17)
Short / Excess income tax provision for earlier years	36.75	-	-	36.75	70.69	60.95
5. Net Profit / (Loss) after tax (3-4)	267.65	(45.20)	(527.86)	104.83	(1,023.07)	(1,203.06)
6. Other Comprehensive Income items that will not be reclassified into Profit or Loss						
- Remeasurement of Defined Benefit Plans (Net of tax)	-	-	-	-	(0.38)	(1.25)
7. Total Comprehensive Income for the year (after tax) (5+6)	267.65	(45.20)	(527.86)	104.83	(1,023.45)	(1,204.31)
8. Paid-up Equity Share Capital (Face Value of Rs. 10/- each)	4,067.27	2,286.44	2,286.44	4,067.27	2,286.44	2,286.44
9. Other Equity excluding Revaluation reserve as per Balance Sheet						8,243.34
10. Earnings per Equity Share (of Rs. 10/- each)						
(a) Basic	0.89	(0.20)	(2.31)	0.42	(4.47)	(5.26)
(b) Diluted	0.89	(0.20)	(2.31)	0.42	(4.47)	(5.26)

Notes :

- The Above Financial Results were reviewed by the audit committee of the board on 10th February, 2020 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditors have expressed on unmodified opinion. The review report has been filed with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind AS notified under the Companies (Accounting Standards) Rule, 2015.
- Other income includes Rs.7.56 lakhs being the net amount of interest reversed on the account of the component of unsecured loan of earlier periods as the same now has been repaid.
- Company has issued and allotted 1,78,08,219 Equity Shares of Rs.10 each at Rs.18.25/-per share including Rs.8.25 on account of share premium on 30th November 2019 to the promoter of the company Dr. Omkar Pravin Herlekar.
- Finance cost includes Gain / (Loss) on account of foreign exchange fluctuations

Quarter / Half year ended	31.12.2019 (Unaudited)	30.09.2019 (Unaudited)	31.12.2018 (Unaudited)	31.12.2019 (Unaudited)	31.12.2018 (Unaudited)	31.03.2019 (Audited)
Foreign Exchange Gain / (Loss)	(15.46)	(46.08)	79.71	(52.76)	(159.73)	(151.16)

- The Company has single business segment i.e. Active Pharmaceutical Ingredients (API), therefore, in the context of Ind AS 108, disclosure of segment information is not applicable.
- Figures of previous period have been re-grouped / reclassified wherever necessary, to confirm to this period's classification.

**By order of the Board of Directors
For Lasa Supergenerics Limited**

Sd/-
Omkar Herlekar
Chairman & Managing Director
(DIN No. 01587154)

Place : Mumbai
Date : 10th February, 2020



Indiabulls Ventures
Regd. Office: M-62 & 63, First Floor, Connaught Place, New Delhi
CIN: L74999DL1995PLC
Email: helpdesk@indiabulls.com,
Fax: 0124-6681240, Website: www.indiabulls.com

**NOTICE
FOR ATTENTION OF THE EQUITY SHAREHOLDERS
SUBJECT : TRANSFER OF EQUITY SHARES
TO INVESTOR EDUCATION AND PROTECTION FUND (IEPF)**

This notice is given pursuant to Investor Education and Protection Fund (IEPF) Act, 1996 and the Rules framed thereunder ('the Rules') as amended from time to time. Notifications issued by the Ministry of Corporate Affairs, Government of India, from time to time.

The Rules and Section 124(6) of the Companies Act, 2013 provide for transfer of all shares, in respect of which the dividend has not been paid or claimed for seven consecutive years to the Investor Education and Protection Fund (IEPF). The provisions of the Rules, the Companies Act, 2013 and the IEPF Act, 1996 require that the shares, individually to the concerned shareholders, be transferred to IEPF suspense account to the extent of the dividend amount(s) on or before March 31, 2020.

Year-wise details of all un-paid/un-claimed dividends of the Company are available on the website of the Company: www.indiabullsventures.com. Shareholders, including their folio number or otherwise, are liable to be transferred to the IEPF suspense account on the date of the transfer of shares to the IEPF.

Shareholders may note that the shares held in dematerialized form are liable to be transferred to the IEPF suspense account along with any accrued benefits on these shares back from the IEPF, following the procedure mentioned in the Rules.

Shareholders may note that following the transfer of shares to the IEPF, the Company will be issuing duplicate share certificates for the purpose of transfer of shares to the IEPF, which the original share certificates will stand void.

In case no communication is received from the shareholders whether holding shares in physical or in dematerialized form, the Company shall initiate such steps as may be necessary to transfer those shares to the IEPF, following the method mentioned in the Rules.

Shareholders having query in this regard are requested to contact the Registrar and Share Transfer Agent of the Company, Ms. C Shobha Anand at Karvy Selenia, Gachibowli, Financial District, Nanakramguda, Hyderabad - 500032, (91 -40) 6716 2222; Toll Free- 1800 -345-4000; e-mail: einward.ris@kfintech.com.

Place: New Delhi
Date: February 11, 2020

PUBLIC NOTICE
Tata Chemicals Limited, road office